naturalX Health Ventures

What naturalX Health Ventures does

naturalX Health Ventures GmbH is a Berlin-based venture capital fund established in 2023 with €100 million in committed capital, purpose-built to invest in consumer health startups at the intersection of wellness and medicine. The fund is backed by Schwabe Group, a 150-year-old global leader in plant-based pharmaceuticals, which provides operational expertise, commercial reach across EU and US markets, and domain heritage in natural health and mental health therapeutics. naturalX targets Series A and Series B rounds primarily, with flexibility to invest from seed to late stage, writing typical tickets of €3-5 million and reserving up to €10 million per portfolio company.

The fund's investment thesis centers on two thematic pillars: proactive health (including prevention and longevity, sleep, nutrition and supplements, bio-hacking, genomics, wearables, digital therapeutics, at-home diagnostics, and remote care) and mental health (leveraging Schwabe's heritage in plant-based mental health pharmaceuticals to back digital and alternative mental health solutions). The active portfolio of 8 companies spans European and US markets, including Ilant Health (obesity care, NYC), Function Health (lab testing, Austin), Jutro Medical (primary care, Warsaw), Hilo (blood pressure wearables, Neuchâtel), Kyan Health (workplace mental health, Zurich), Flow Neuroscience (brain stimulation, Malmö), Meela (therapist matching, Gothenburg), and mybacs (microbiome, Zurich).

The firm operates with a lean team of 1-10 employees led by Managing Directors Oliver Schulz and Marvin Amberg, with an investment committee chaired by the Schwabe Group CEO providing strategic oversight. Revenue mechanics follow standard VC fund economics: management fees on committed capital, with carried interest accruing over the fund's life. Beyond direct equity investments, naturalX also participates as a limited partner in other funds and publishes annual consumer health industry research ('This Year in Consumer Health Report') to build category authority and source deal flow.

Name

naturalX Health Ventures

Legal name

naturalX Health Ventures

Website

https://naturalx.vc

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

naturalX Health Ventures is a Berlin-based €100 million venture capital fund backed by Schwabe Group, investing in consumer health startups at Series A and B stages across Europe and the US, with a focus on proactive health and mental health.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital Fund Management

akta.pro primary industry

Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

akta.pro secondary industry

Corporate Fintech / Insurtech CVC (Financial-services-led CVC) (FSANAHAK)

Keywords

• Venture capital fund
• Consumer health investing
• Healthcare venture capital
• Startup growth funding
• Digital health investments

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels1 record

Marketing channels3 records

Core offering

naturalX Health Ventures is a €100 million venture capital fund that makes direct equity investments into consumer health startups at the intersection of wellness and medicine. The fund focuses on Series A and Series B rounds with a typical ticket of €3-5 million (reserving up to €10 million per company), and can invest from seed to late stage. It is backed by Schwabe Group, a global leader in plant-based pharmaceuticals with 150 years of natural health heritage.

Product overview

naturalX Health Ventures is a venture capital fund, not a product company. It operates as a €100 million investment vehicle backed by Schwabe Group, focusing on consumer health investments from seed to late stage, with particular emphasis on Series A and Series B. The firm publishes an annual consumer health industry report (This Year in Consumer Health Report 2026).

Differentiator

Problem solved

Functional benefit

Products and services

• naturalX Health Ventures Fund

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Forerunner Ventures: US-based leading consumer-focused venture firm that has backed category-defining consumer brands. While broader than naturalX, it shares a consumer-led thesis overlapping with naturalX's consumer health and wellness bets.
• Novo Holdings (Seed Investments): Denmark-based holding and investment company of the Novo Nordisk Foundation, investing broadly across life sciences, biotech, and digital health. Comparable as a strategic-backed European health investor with deep pockets.
• Speedinvest: Vienna-based early-stage European venture firm with a dedicated Health & TechBio vertical. Comparable for its European digital-health focus and early-stage Series A activity, though broader than naturalX.
• EQT Life Sciences (formerly LSP): European life-sciences and health-tech investor part of the EQT platform, investing across stages in healthcare innovation. Comparable as a European institutional health VC with similar investment horizons and ticket sizes.

Direct peers

• Sanofi Ventures: Corporate venture arm of a global pharmaceutical company investing in digital health, biotech, and consumer health adjacencies. Closely comparable to naturalX as a strategic-corporate-backed health VC, with similar ticket sizes and stage focus.
• Bayer G4A (formerly Grants4Apps): Bayer's corporate venture and partnership initiative backing digital health and consumer health startups. Directly comparable as another pharma-strategic-backed investor targeting the consumer/digital health intersection.
• Define Ventures: US venture firm exclusively focused on digital health and consumer health companies, investing in early to growth stages. Highly comparable specialist thesis to naturalX, though US-anchored and larger AUM.
• Boehringer Ingelheim Venture Fund: Corporate venture arm of a major pharma group investing in early-stage health and biotech innovation. Comparable as a European pharma-strategic VC with deep operational support capabilities for portfolio companies.
• Earlybird Health: Berlin-based early-stage venture fund specifically dedicated to healthcare and health tech. Highly comparable as a European specialist health VC operating in similar Series A/B ticket sizes and adjacent digital health themes.
• Flare Capital Partners: US venture firm exclusively focused on early-stage digital health, health tech, and consumer health innovation. Comparable specialist thesis and stage focus to naturalX, though US-anchored.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/naturalx-health-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about naturalX Health Ventures